DE69433981D1 - Biocompatibele okulare implantate - Google Patents

Biocompatibele okulare implantate

Info

Publication number
DE69433981D1
DE69433981D1 DE69433981T DE69433981T DE69433981D1 DE 69433981 D1 DE69433981 D1 DE 69433981D1 DE 69433981 T DE69433981 T DE 69433981T DE 69433981 T DE69433981 T DE 69433981T DE 69433981 D1 DE69433981 D1 DE 69433981D1
Authority
DE
Germany
Prior art keywords
ocular implants
administration
implants
biocompatible ocular
biocompatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433981T
Other languages
English (en)
Other versions
DE69433981T2 (de
Inventor
G Wong
Frank Kochinke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE69433981D1 publication Critical patent/DE69433981D1/de
Application granted granted Critical
Publication of DE69433981T2 publication Critical patent/DE69433981T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69433981T 1993-11-15 1994-11-09 Biocompatibele okulare implantate Expired - Lifetime DE69433981T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/153,184 US5443505A (en) 1993-11-15 1993-11-15 Biocompatible ocular implants
US153184 1993-11-15
PCT/US1994/012898 WO1995013765A1 (en) 1993-11-15 1994-11-09 Biocompatible ocular implants

Publications (2)

Publication Number Publication Date
DE69433981D1 true DE69433981D1 (de) 2004-10-07
DE69433981T2 DE69433981T2 (de) 2005-09-01

Family

ID=22546138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433981T Expired - Lifetime DE69433981T2 (de) 1993-11-15 1994-11-09 Biocompatibele okulare implantate

Country Status (11)

Country Link
US (3) US5443505A (de)
EP (1) EP0729324B1 (de)
JP (1) JPH09505300A (de)
KR (1) KR960705512A (de)
CN (1) CN1139375A (de)
AT (1) ATE274872T1 (de)
AU (1) AU1092495A (de)
DE (1) DE69433981T2 (de)
ES (1) ES2231781T3 (de)
TW (1) TW368411B (de)
WO (1) WO1995013765A1 (de)

Families Citing this family (544)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435141D1 (de) 1993-07-19 2008-10-30 Angiotech Pharm Inc Anti-angiogene Mittel und Verfahren zu deren Verwendung
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5620013A (en) * 1994-10-21 1997-04-15 American Cyanamid Company Method for destroying residual lens epithelial cells
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6063370A (en) * 1996-04-05 2000-05-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
DE69827138T2 (de) * 1997-08-11 2006-02-23 Allergan, Inc., Irvine Steriles Retinoid enthaltendes biodegradierbares Implantat mit verbesserter Biokompatibilität und Verfahren zu dessen Herstellung
US6007578A (en) 1997-10-08 1999-12-28 Ras Holding Corp Scleral prosthesis for treatment of presbyopia and other eye disorders
US6991650B2 (en) 1997-10-08 2006-01-31 Refocus Ocular, Inc. Scleral expansion device having duck bill
DE69926017T2 (de) * 1998-04-27 2005-12-22 SurModics, Inc., Eden Prairie Bioaktive Wirkstoffe freisetzende Beschichtungen
WO2000000106A1 (en) * 1998-06-29 2000-01-06 Rozakis George W Antioxidant intraocular lens
US6024719A (en) * 1998-07-06 2000-02-15 Morris; Robert E Method and apparatus for performing surgery inside the human retina using fluidic internal limiting membrane (ILM) seperation (FILMS)
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6309374B1 (en) 1998-08-03 2001-10-30 Insite Vision Incorporated Injection apparatus and method of using same
FR2787991B1 (fr) * 1998-12-31 2001-05-25 Medicale De Prec S M P Sa Soc Dispositif pour traiter la presbytie ou autre affection oculaire
JP2002534139A (ja) * 1999-01-05 2002-10-15 マサチューセッツ・アイ・アンド・イア・インファーマリー 網膜と脈絡膜への経強膜徐放性薬剤標的送達
US6113638A (en) * 1999-02-26 2000-09-05 Williams; Lytton A. Method and apparatus for intervertebral implant anchorage
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
JP3703721B2 (ja) 1999-04-26 2005-10-05 ジーエムピー ヴィジョン ソルーションズ インコーポレイテッド 緑内障を治療するためのシャント装置
US6699210B2 (en) * 1999-04-27 2004-03-02 The Arizona Board Of Regents Glaucoma shunt and a method of making and surgically implanting the same
WO2000074600A1 (en) 1999-06-07 2000-12-14 Ras Holding Corporation Improved scleral prosthesis for treatment of presbyopia and other eye disorders
US7008396B1 (en) 1999-09-03 2006-03-07 Restorvision, Inc. Ophthalmic device and method of manufacture and use
DE19947711B4 (de) * 1999-10-04 2004-02-12 Schrage, Norbert, Priv. Doz. Dr.med. Implantat zum Eisatz in der Glaukomtherapie
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
CN1292721C (zh) 1999-10-21 2007-01-03 爱尔康公司 药物释放装置
ES2240180T3 (es) 1999-10-21 2005-10-16 Alcon Inc. Administracion sub-tenon de medicamentos.
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
US20050277864A1 (en) * 2000-04-14 2005-12-15 David Haffner Injectable gel implant for glaucoma treatment
US6638239B1 (en) 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
US20020143284A1 (en) * 2001-04-03 2002-10-03 Hosheng Tu Drug-releasing trabecular implant for glaucoma treatment
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US20040111050A1 (en) * 2000-04-14 2004-06-10 Gregory Smedley Implantable ocular pump to reduce intraocular pressure
US20050049578A1 (en) * 2000-04-14 2005-03-03 Hosheng Tu Implantable ocular pump to reduce intraocular pressure
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6417237B1 (en) 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
EP1637126B1 (de) * 2000-07-05 2016-12-14 Allergan, Inc. Verfahren zur Behandlung von entzündungsbedingten Zuständen der Augen
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
ES2312456T3 (es) * 2000-08-30 2009-03-01 Johns Hopkins University Dispositivos para suministro intraocular de farmacos.
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
ATE306951T1 (de) 2000-11-29 2005-11-15 Allergan Inc Verhinderung von transplantatabstossung im auge
ATE359762T1 (de) 2001-01-09 2007-05-15 Microchips Inc Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6981958B1 (en) * 2001-05-02 2006-01-03 Glaukos Corporation Implant with pressure sensor for glaucoma treatment
US7488303B1 (en) * 2002-09-21 2009-02-10 Glaukos Corporation Ocular implant with anchor and multiple openings
WO2002080811A2 (en) 2001-04-07 2002-10-17 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
US7678065B2 (en) 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US7094225B2 (en) 2001-05-03 2006-08-22 Glaukos Corporation Medical device and methods of use of glaucoma treatment
US20060241750A1 (en) * 2001-05-22 2006-10-26 Ras Holding Corp Scleral expansion device having duck bill
EP2316394B1 (de) * 2001-06-12 2016-11-23 The Johns Hopkins University Reservoirvorrichtung für die intraokulare Arzneimittelabgabe
US7592016B2 (en) * 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20050119742A1 (en) * 2001-06-30 2005-06-02 Richter Paul W. Orbital implant
DE10133870A1 (de) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmisches Mittel, Verwendung von EGF zur Behandlung von Dry Eye-Syndrom und Insert zur Verabreichung von EGF am Auge
BR0210287A (pt) * 2001-07-23 2005-12-13 Alcon Inc Dispositivo de administração de droga oftalmológica
DE60217679T2 (de) 2001-07-23 2007-10-25 Alcon Inc. Vorrichtung zur freisetzung eines ophthalmischen arzneimittels
US8267995B2 (en) * 2001-08-03 2012-09-18 David Castillejos Method and intra sclera implant for treatment of glaucoma and presbyopia
US7331984B2 (en) 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
CA2456025C (en) * 2001-08-29 2011-11-22 Ricardo A.P. De Carvalho An implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
IN2014DN10834A (de) * 2001-09-17 2015-09-04 Psivida Inc
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
US7186232B1 (en) 2002-03-07 2007-03-06 Glaukoa Corporation Fluid infusion methods for glaucoma treatment
US7621907B2 (en) * 2002-03-11 2009-11-24 Alcon, Inc. Implantable drug delivery system
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US20040147870A1 (en) * 2002-04-08 2004-07-29 Burns Thomas W. Glaucoma treatment kit
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US20040024345A1 (en) * 2002-04-19 2004-02-05 Morteza Gharib Glaucoma implant with valveless flow bias
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
BR0309844A (pt) * 2002-05-07 2005-02-15 Control Delivery Sys Inc Processos para formação de um dispositivo para a distribuição de droga
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
ES2277087T3 (es) * 2002-07-09 2007-07-01 Aecc Enterprises Limited Metodo para representacion con imagenes el movimiento relativo de segmentos esqueleticos.
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
JP4463681B2 (ja) * 2002-07-15 2010-05-19 アルコン，インコーポレイテッド 眼内使用のための非ポリマー親油性薬学的インプラント組成物
US20070027537A1 (en) * 2002-08-02 2007-02-01 David Castillejos Method and intra-sclera implant for treatment of glaucoma and presbyopia
AU2003273339B2 (en) * 2002-09-17 2008-08-14 Iscience Interventional Corporation Apparatus and method for surgical bypass of aqueous humor
US20050203542A1 (en) * 2002-09-18 2005-09-15 Allergan, Inc. Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events
TWI282271B (en) 2002-09-18 2007-06-11 Allergan Inc Apparatus for delivery of ocular implants
US7468065B2 (en) 2002-09-18 2008-12-23 Allergan, Inc. Apparatus for delivery of ocular implants
US6899717B2 (en) * 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US20040221855A1 (en) * 2002-10-17 2004-11-11 Paul Ashton Methods for monitoring treatment of disease
US20040111144A1 (en) * 2002-12-06 2004-06-10 Lawin Laurie R. Barriers for polymeric coatings
CN1747950A (zh) * 2002-12-19 2006-03-15 美国辉瑞有限公司 用于治疗眼病的作为蛋白激酶抑制剂的2－(1h－吲唑－6－基氨基)－苯甲酰胺化合物
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
AU2003297511B2 (en) * 2002-12-20 2010-01-21 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US8185209B2 (en) * 2003-01-03 2012-05-22 Board Of Trustees Operating Michigan State University Methods to extend vision to infrared wavelengths
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20060167435A1 (en) * 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
EP1633320A2 (de) 2003-05-02 2006-03-15 SurModics, Inc. Implantierbares system zur kontrollierten freisetzung eines bioaktiven wirkstoffs
US20040225250A1 (en) 2003-05-05 2004-11-11 Michael Yablonski Internal shunt and method for treating glaucoma
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
CA2522592A1 (en) * 2003-07-10 2005-02-03 Alcon, Inc. Ophthalmic drug delivery device
ES2391975T3 (es) * 2003-07-25 2012-12-03 Genvec, Inc. Vacunas a base de vector adenovírico
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005048873A2 (en) * 2003-11-12 2005-06-02 Alcon, Inc. Kit for administration of a drug
ES2340389T3 (es) * 2003-11-13 2010-06-02 Psivida Us Inc. Implante inyectable de liberacion prolongada que comprende un nucleo de matriz bioerosionable y una piel bioerosionable.
ATE458500T1 (de) * 2003-11-14 2010-03-15 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
US7291125B2 (en) * 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
WO2005051328A2 (en) 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration of macular degeneration and other ophthalmic diseases
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US7211272B2 (en) * 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050250788A1 (en) * 2004-01-30 2005-11-10 Hosheng Tu Aqueous outflow enhancement with vasodilated aqueous cavity
US20050244459A1 (en) 2004-04-06 2005-11-03 Dewitt David M Coating compositions for bioactive agents
JP2007532656A (ja) 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
US7691381B2 (en) 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
EP2468327A1 (de) * 2004-04-29 2012-06-27 iScience Interventional Corporation Vorrichtung und Verfahren zur chirurgischen Verbesserung einer Kammerwasserdrainage
US20080058704A1 (en) * 2004-04-29 2008-03-06 Michael Hee Apparatus and Method for Ocular Treatment
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
AU2011213904B2 (en) * 2004-04-30 2014-06-05 Allergan, Inc. Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
BRPI0513243B8 (pt) * 2004-07-12 2021-05-25 Allergan Inc composições oftálmicas e respectivos usos
WO2006020071A2 (en) 2004-07-16 2006-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccines against aids comprising cmv/r-nucleic acid constructs
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US7722669B2 (en) * 2004-08-13 2010-05-25 Richard Foulkes Method and insert for modifying eye color
US8246569B1 (en) 2004-08-17 2012-08-21 California Institute Of Technology Implantable intraocular pressure drain
US20060047250A1 (en) * 2004-08-30 2006-03-02 Hickingbotham Dyson W Fluid delivery device
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
CN100428958C (zh) * 2004-09-06 2008-10-29 段亚东 一种治疗眼病的植入剂
EP2452670A1 (de) 2004-10-01 2012-05-16 Ramscor, Inc. Einfach implantierbare Arzneimittelzusammensetzungen mit verzögerter Freisetzung
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US7226435B2 (en) * 2004-10-14 2007-06-05 Alcon, Inc. Drug delivery device
US20060089590A1 (en) * 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20070104931A (ko) * 2005-02-09 2007-10-29 마커사이트, 인코포레이티드 안구 치료용 제제
US7699863B2 (en) * 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US7785291B2 (en) * 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US7452868B2 (en) * 2005-03-11 2008-11-18 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
AU2006227116A1 (en) * 2005-03-21 2006-09-28 Santen Pharmaceutical Co., Ltd. Drug delivery systems for treatment of diseases or conditions
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20060258994A1 (en) * 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
EP1919365A2 (de) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Okular-plug aus kollagen-biogewebe aus plazenta
AU2006270094A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Prevention and treatment of ophthalmic complications of diabetes
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20070060887A1 (en) * 2005-08-22 2007-03-15 Marsh David A Ophthalmic injector
JP2009505680A (ja) * 2005-08-31 2009-02-12 ジェンベク、インコーポレイティッド アデノウイルスベクターに基づくマラリアワクチン
CA2850858A1 (en) * 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
MX339797B (es) * 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US9067047B2 (en) * 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
EP1951297A2 (de) * 2005-11-10 2008-08-06 GenVec, Inc. Adenoviraler vektorbasierter impfstoff für die maul- und klauen-seuche
WO2007064752A2 (en) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EP3338743A1 (de) * 2006-01-17 2018-06-27 Novartis Ag Behandlungsvorrichtung für wirkstofffreisetzung
ES2551782T3 (es) 2006-01-17 2015-11-23 Transcend Medical, Inc. Dispositivo para el tratamiento de glaucoma
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
AU2007293169A1 (en) 2006-02-02 2008-03-13 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
US20080140057A1 (en) * 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
CA2833354C (en) * 2006-03-14 2015-12-15 University Of Southern California Mems device and method for delivery of therapeutic agents
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US8795711B2 (en) 2006-03-31 2014-08-05 Mati Therapeutics Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
US8676293B2 (en) * 2006-04-13 2014-03-18 Aecc Enterprises Ltd. Devices, systems and methods for measuring and evaluating the motion and function of joint structures and associated muscles, determining suitability for orthopedic intervention, and evaluating efficacy of orthopedic intervention
US20070293807A1 (en) * 2006-05-01 2007-12-20 Lynch Mary G Dual drainage pathway shunt device and method for treating glaucoma
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US20070268340A1 (en) * 2006-05-17 2007-11-22 Bruno Dacquay Ophthalmic Injection System and Method Using Piezoelectric Array
US7811252B2 (en) * 2006-05-17 2010-10-12 Alcon Research, Ltd. Dosage control device
US20070270768A1 (en) * 2006-05-17 2007-11-22 Bruno Dacquay Mechanical Linkage Mechanism For Ophthalmic Injection Device
US20070270744A1 (en) * 2006-05-17 2007-11-22 Bruno Dacquay Limited Reuse Assembly For Ophthalmic Injection Device
US7674243B2 (en) * 2006-05-17 2010-03-09 Alcon Inc. Ophthalmic injection device using piezoelectric array
US7862540B2 (en) * 2006-05-17 2011-01-04 Alcon Research, Ltd. Ophthalmic injection device using shape memory alloy
US20070270750A1 (en) * 2006-05-17 2007-11-22 Alcon, Inc. Drug delivery device
US7887521B2 (en) * 2006-05-17 2011-02-15 Alcon Research, Ltd. Ophthalmic injection system
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US10085884B2 (en) 2006-06-30 2018-10-02 Aquesys, Inc. Intraocular devices
US8663303B2 (en) 2010-11-15 2014-03-04 Aquesys, Inc. Methods for deploying an intraocular shunt from a deployment device and into an eye
WO2008005873A2 (en) 2006-06-30 2008-01-10 Aquesys Inc. Methods, systems and apparatus for relieving pressure in an organ
US8308701B2 (en) 2010-11-15 2012-11-13 Aquesys, Inc. Methods for deploying intraocular shunts
US20120123316A1 (en) 2010-11-15 2012-05-17 Aquesys, Inc. Intraocular shunts for placement in the intra-tenon's space
US9095411B2 (en) 2010-11-15 2015-08-04 Aquesys, Inc. Devices for deploying intraocular shunts
US8721702B2 (en) 2010-11-15 2014-05-13 Aquesys, Inc. Intraocular shunt deployment devices
US8852256B2 (en) 2010-11-15 2014-10-07 Aquesys, Inc. Methods for intraocular shunt placement
AU2007272963B2 (en) 2006-07-11 2013-05-23 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
US8911496B2 (en) 2006-07-11 2014-12-16 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
US20080097335A1 (en) * 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
AU2007286630A1 (en) 2006-08-23 2008-02-28 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derivatives of uric and thiouric acid for oxidative stress-related diseases
EP2059282A4 (de) * 2006-09-06 2014-04-09 Innfocus Inc Vorrichtung, verfahren und geräte zur behandlung von augenerkrankungen
US20080097379A1 (en) * 2006-09-26 2008-04-24 Alcon Manufacturing, Ltd. Ophthalmic injection method
US20080125712A1 (en) * 2006-09-26 2008-05-29 Alcon Manufacturing, Ltd. Ophthalmic injection system
US20080097390A1 (en) * 2006-09-27 2008-04-24 Alcon Manufacturing, Ltd. Spring actuated delivery system
CA2664879C (en) * 2006-09-29 2015-03-24 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
US20080091178A1 (en) * 2006-10-11 2008-04-17 Sunalp Murad A Device and method for medical records storage in the eye
RU2009118415A (ru) * 2006-10-16 2010-11-27 Алькон Рисерч, Лтд. (Us) Способ управления работой офтальмологического ручного инструмента с наконечником одноразового использования
US9022970B2 (en) * 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
EP2063829B1 (de) * 2006-10-16 2010-12-08 Alcon Research, Ltd. Universelle aufladbare baugruppe mit eingeschränkter wiederverwendbarkeit für ein ophthalmisches handstück
US20080281292A1 (en) * 2006-10-16 2008-11-13 Hickingbotham Dyson W Retractable Injection Port
US8586556B2 (en) 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2008061043A2 (en) 2006-11-10 2008-05-22 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US20100034808A1 (en) * 2006-11-21 2010-02-11 Toru Nakazawa Compositions and methods for preserving cells of the eye
EP2727936B1 (de) 2006-11-22 2016-09-07 Bristol-Myers Squibb Company Gezielte Therapeutik auf Grundlage manipulierter Proteine für Tyrosinkinaserezeptoren, einschließlich IGF-IR
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008070479A2 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US20080140024A1 (en) * 2006-12-08 2008-06-12 Yoseph Yaacobi Drug delivery device
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
EP2114445A2 (de) * 2007-01-09 2009-11-11 Genvec, Inc. Auf adenoviralen vektoren basierende malaria-impfstoffe
JP4957258B2 (ja) * 2007-01-15 2012-06-20 富士通株式会社 歩数計数装置および歩数計数方法
GB0713463D0 (en) 2007-07-11 2007-08-22 Btg Int Ltd Modulators of hypoxia inducible factor-1 and related uses
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
WO2008157614A2 (en) * 2007-06-21 2008-12-24 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US20090018548A1 (en) * 2007-07-13 2009-01-15 Charles Steven T Pneumatically-Powered Intraocular Lens Injection Device with Removable Cartridge
US20090018512A1 (en) * 2007-07-13 2009-01-15 Charles Steven T Pneumatically-Powered Ophthalmic Injector
EP2173289A4 (de) 2007-07-17 2010-11-24 Transcend Medical Inc Augenimplantat mit hydrogelausdehnungsfähigkeiten
US7740619B2 (en) * 2007-08-01 2010-06-22 Alcon Research, Ltd. Spring driven ophthalmic injection device with safety actuator lockout feature
AU2008282181B2 (en) * 2007-08-02 2014-01-16 Refocus Group, Inc. Scleral prosthesis having crossbars for treating presbyopia and other eye disorders
US7629768B2 (en) * 2007-08-03 2009-12-08 Alcon Research, Ltd. Easy cleaning C-shaped charging base
US20090036842A1 (en) * 2007-08-03 2009-02-05 Raffi Pinedjian Consumable Activation Lever For Injection Device
EP2205193A2 (de) 2007-09-07 2010-07-14 QLT Plug Delivery, Inc. Nachweis eines lakrimalen implantats
TWI498136B (zh) * 2007-10-09 2015-09-01 Alcon Res Ltd 用於遞送速率及溫度相依性物質至眼睛的注射器及其製備方法
TWI451862B (zh) * 2007-10-09 2014-09-11 Alcon Res Ltd 用於眼睛注射的熱係數驅動藥丸尺寸
US20090099481A1 (en) 2007-10-10 2009-04-16 Adam Deitz Devices, Systems and Methods for Measuring and Evaluating the Motion and Function of Joints and Associated Muscles
BRPI0820176B8 (pt) 2007-11-08 2021-06-22 Alimera Sciences Inc dispositivo de implantação ocular e kit para liberar um implante
US9308124B2 (en) * 2007-12-20 2016-04-12 University Of Southern California Apparatus and methods for delivering therapeutic agents
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US20090162417A1 (en) * 2007-12-21 2009-06-25 Cook Incorporated Drug eluting ocular conformer
MX2010007382A (es) 2008-01-03 2010-12-20 Univ Southern California Dispositivos implantables para suministro de farmacos, y aparato y metodos para recargar los dispositivos.
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
US20100152646A1 (en) * 2008-02-29 2010-06-17 Reshma Girijavallabhan Intravitreal injection device and method
US20090227938A1 (en) * 2008-03-05 2009-09-10 Insitu Therapeutics, Inc. Wound Closure Devices, Methods of Use, and Kits
US8231609B2 (en) 2008-05-08 2012-07-31 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9849238B2 (en) 2008-05-08 2017-12-26 Minipumps, Llc Drug-delivery pump with intelligent control
MX2010012213A (es) * 2008-05-08 2011-05-03 Minipumps Llc Bombas implantables y cánulas para las mismas.
JP2011519695A (ja) 2008-05-08 2011-07-14 リプレニッシュ パンプス， エルエルシー 植設可能な薬物送達デバイスおよびそのデバイスを充填する装置および方法
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
US8617139B2 (en) 2008-06-25 2013-12-31 Transcend Medical, Inc. Ocular implant with shape change capabilities
EP2320911B1 (de) 2008-08-01 2014-10-08 Eye Therapies LLC Gefässverengungszusammensetzungen und verfahren zu ihrer verwendung
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
US20100121441A1 (en) * 2008-11-10 2010-05-13 Nabil Jabbour Surgical implant and method
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
US8551167B2 (en) 2008-11-20 2013-10-08 Insight Innovations, Llc Intraocular implant cell migration inhibition system
US20120232649A1 (en) 2008-11-20 2012-09-13 Insight Innovations, Llc Intraocular Lens Cell Migration Inhibition System
MX2011005272A (es) * 2008-11-20 2011-06-21 Insight Innovations Llc Sistema de implante intraocular biocompatible biodegradable.
US9943402B2 (en) 2008-11-20 2018-04-17 Insight Innovations, Llc Micropatterned intraocular implant
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US20100158980A1 (en) 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US8425473B2 (en) 2009-01-23 2013-04-23 Iscience Interventional Corporation Subretinal access device
US20100191177A1 (en) * 2009-01-23 2010-07-29 Iscience Interventional Corporation Device for aspirating fluids
EP3735947B1 (de) 2009-01-28 2022-05-04 Alcon Inc. System zum einbringen eines augenimplantats
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
EP2391419B1 (de) 2009-01-29 2019-06-12 ForSight Vision4, Inc. Wirkstofffreisetzung im hinteren augensegment
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
JP5342301B2 (ja) * 2009-03-30 2013-11-13 三菱重工業株式会社 太陽光集光受熱器
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN102596097B (zh) 2009-06-03 2015-05-20 弗赛特实验室有限责任公司 一种眼插入件
IN2012DN00352A (de) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2010148352A1 (en) 2009-06-19 2010-12-23 Altos Vision Limited Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
JP5758388B2 (ja) 2009-08-18 2015-08-05 ミニパンプス， エルエルシー 適応制御を有する電解質薬物送達ポンプ
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2011038236A2 (en) 2009-09-25 2011-03-31 Ortho Kinematics, Inc. Systems and devices for an integrated imaging system with real-time feedback loops and methods therefor
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
JP5886204B2 (ja) * 2009-10-30 2016-03-16 アトーン ファルマ、インコーポレイテッドＡｔｏｎ Ｐｈａｒｍａ，Ｉｎｃ． 眼内薬剤送達装置
KR101769637B1 (ko) 2009-11-09 2017-08-18 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
EP2498778A1 (de) 2009-11-13 2012-09-19 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Diazeniumdiolatverbindungen, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
JP2013515741A (ja) * 2009-12-23 2013-05-09 サイヴィーダ ユーエス，インコーポレイテッド 持続放出性送達デバイス
EP2538965B1 (de) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges
ES2887335T3 (es) 2010-03-17 2021-12-22 Univ Cornell Vacuna contra las drogas de abuso basada en adenovirus alterado
EP2547660B1 (de) 2010-03-19 2015-01-07 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Nitroxyl (hno)-freisetzende verbindungen und ihre verwendung zur behandlung von erkrankungen
WO2011133964A2 (en) 2010-04-23 2011-10-27 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
EP2383286A1 (de) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und Zusammensetzungen zur Behandlung von degenerativen Netzhauterkrankungen
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
AU2011256259A1 (en) 2010-05-17 2012-11-08 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents
CN103180339B (zh) 2010-05-26 2016-04-27 百时美施贵宝公司 具有改善的稳定性的基于纤连蛋白的支架蛋白质
JP6111194B2 (ja) 2010-08-05 2017-04-05 フォーサイト・ビジョン フォー・インコーポレーテッド 組み合わせ薬物送達方法および装置
PT2600812T (pt) * 2010-08-05 2021-11-09 Forsight Vision4 Inc Aparelho para tratar um olho
AU2011285545B2 (en) 2010-08-05 2014-03-13 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
JP5996544B2 (ja) * 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
WO2012061045A2 (en) 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
US20160256319A1 (en) 2010-11-15 2016-09-08 Aquesys, Inc. Intraocular shunt placement in the suprachoroidal space
EP2640360A2 (de) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutische wirkstoffformulierungen für implantierte vorrichtungen
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
EP2651295A4 (de) 2010-12-13 2015-11-18 Ortho Kinematics Inc Verfahren, systeme und vorrichtungen zur berichterstattung über klinische daten und für chirurgische navigation
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
WO2012114138A1 (fr) 2011-02-21 2012-08-30 Cerebel-Invest Sa Implants biodégradables pour la libération contrôlée sous-conjonctivale d'une molécule active
US9919099B2 (en) 2011-03-14 2018-03-20 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9603997B2 (en) 2011-03-14 2017-03-28 Minipumps, Llc Implantable drug pumps and refill devices therefor
US10286146B2 (en) 2011-03-14 2019-05-14 Minipumps, Llc Implantable drug pumps and refill devices therefor
EP2691127B1 (de) * 2011-03-27 2021-01-13 Microsert Ltd Implantierbare miniatur-arzneimittelabgabevorrichtungen und einführsystem zur einführung solcher vorrichtungen
US9012647B2 (en) 2011-04-07 2015-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
WO2012149452A1 (en) 2011-04-29 2012-11-01 Regents Of The University Of Michigan Compounds, formulations, and methods of protein kinase c inhibition
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
WO2012167223A1 (en) 2011-06-02 2012-12-06 Massachusetts Institute Of Technology Modified alginates for cell encapsulation and cell therapy
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
BR112013032199A2 (pt) 2011-06-14 2017-12-12 Bikam Pharmaceuticals Inc ligantes de ligação à opsina, composições e métodos de utilização
US20150005254A1 (en) 2011-06-27 2015-01-01 Massachusetts Eye And Ear Infirmary Methods for treating ocular inflammatory disorders
EP4249059A3 (de) 2011-06-28 2023-11-29 ForSight Vision4, Inc. Vorrichtung zum sammeln einer flüssigkeitsprobe aus einer reservoirkammer einer therapeutischen vorrichtung für das auge
EP2739252A4 (de) 2011-08-05 2015-08-12 Forsight Vision4 Inc Abgabe kleiner moleküle über eine implantierbare therapeutische vorrichtung
US9724357B2 (en) 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
US11363951B2 (en) 2011-09-13 2022-06-21 Glaukos Corporation Intraocular physiological sensor
CN103917202B (zh) 2011-09-14 2016-06-29 弗赛特影像5股份有限公司 眼插入件装置和方法
HUE054578T2 (hu) 2011-09-16 2021-09-28 Forsight Vision4 Inc Fluidumcserélõ berendezés
CA2849192C (en) 2011-10-12 2019-09-24 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
EP2768307B1 (de) 2011-10-19 2020-03-18 Bikam Pharmaceuticals, Inc. Opsinbindende liganden, zusammensetzungen damit und anwendungsverfahren dafür
US20140357570A1 (en) 2011-10-21 2014-12-04 Massachusetts Eye And Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
AU2012346214B2 (en) 2011-11-30 2017-09-14 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US10040749B2 (en) 2011-12-01 2018-08-07 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
US9808373B2 (en) 2013-06-28 2017-11-07 Aquesys, Inc. Intraocular shunt implantation
US10080682B2 (en) 2011-12-08 2018-09-25 Aquesys, Inc. Intrascleral shunt placement
US8765210B2 (en) 2011-12-08 2014-07-01 Aquesys, Inc. Systems and methods for making gelatin shunts
US8852136B2 (en) * 2011-12-08 2014-10-07 Aquesys, Inc. Methods for placing a shunt into the intra-scleral space
US9610195B2 (en) 2013-02-27 2017-04-04 Aquesys, Inc. Intraocular shunt implantation methods and devices
US9241829B2 (en) * 2011-12-20 2016-01-26 Abbott Medical Optics Inc. Implantable intraocular drug delivery apparatus, system and method
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US20150038557A1 (en) 2012-02-24 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treatment of retinal degenerative diseases
WO2013130393A1 (en) 2012-02-28 2013-09-06 Cornell University Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
WO2013154744A1 (en) 2012-04-13 2013-10-17 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
WO2013183058A2 (en) 2012-06-07 2013-12-12 Tulip Medical Ltd. Expanded device
ES2633185T3 (es) 2012-09-17 2017-09-19 Novartis Ag Dispositivos de implante ocular expansibles
RU2676102C2 (ru) 2012-09-27 2018-12-26 Аллерган, Инк. Биодеградируемые системы доставки лекарственных средств для долговременного высвобождения белков
EP2911623B1 (de) 2012-10-26 2019-08-14 Forsight Vision5, Inc. Ophthalmisches system für die verzögerte freisetzung von arzneimitteln ins auge
CN104884049A (zh) 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
WO2014078288A1 (en) 2012-11-14 2014-05-22 Transcend Medical, Inc. Flow promoting ocular implant
SI3660033T1 (sl) 2012-11-15 2021-09-30 Apellis Pharmaceuticals, Inc. Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki
WO2014093270A1 (en) 2012-12-10 2014-06-19 Virginia Commonwealth University Tropism modified cancer terminator virus (ad.5/3 ctv;ad.5/3-ctv-m7)
EP2953950B1 (de) 2013-02-11 2021-01-13 The Regents of The University of California Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
BR112015019546A2 (pt) 2013-02-15 2017-07-18 Allergan Inc implante de distribuição de drogas prolongado
ES2771478T3 (es) 2013-02-18 2020-07-06 Vegenics Pty Ltd Moléculas de unión a ligando y usos de las mismas
US10159600B2 (en) 2013-02-19 2018-12-25 Aquesys, Inc. Adjustable intraocular flow regulation
US9125723B2 (en) 2013-02-19 2015-09-08 Aquesys, Inc. Adjustable glaucoma implant
WO2014164704A2 (en) 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
CA2940513C (en) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
EP2978393B1 (de) 2013-03-28 2023-12-27 ForSight Vision4, Inc. Augenimplantat zur abgabe von therapeutischen substanzen
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US10098836B2 (en) 2013-05-02 2018-10-16 Retina Foundation Of The Southwest Method for forming a molded two-layer ocular implant
MX2015015282A (es) 2013-05-03 2016-02-26 Clearside Biomedical Inc Aparatos y metodos para inyeccion ocular.
EP2994758B1 (de) 2013-05-08 2017-12-20 Opthea Limited Biomarker für altersbedingte makuladegeneration (amd)
US20160355573A1 (en) 2013-09-05 2016-12-08 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
MY177958A (en) 2013-10-31 2020-09-28 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
US10087224B2 (en) 2013-11-01 2018-10-02 Cornell University Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
ES2740352T3 (es) 2013-11-14 2020-02-05 Eyed Pharma Dispositivo ocular
BR122020011777B1 (pt) 2013-11-14 2022-01-25 AqueSys, Inc Dispositivo de inserção para o tratamento de glaucoma
CA2932574C (en) 2013-12-05 2023-03-07 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
EP3087080B1 (de) 2013-12-24 2018-11-28 President and Fellows of Harvard College Cortistatin-analoga, synthese und verwendungen
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
WO2015112739A1 (en) 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
WO2015123365A1 (en) 2014-02-11 2015-08-20 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP3957735A1 (de) 2014-03-05 2022-02-23 Editas Medicine, Inc. Verfahren im zusammenhang mit crispr/cas und verfahren zur behandlung des usher-syndroms und von retinitis pigmentosa
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
WO2016011191A1 (en) 2014-07-15 2016-01-21 Forsight Vision4, Inc. Ocular implant delivery device and method
US10426735B2 (en) 2014-08-01 2019-10-01 Massachusetts Institute Of Technology Modified alginates for anti-fibrotic materials and applications
EP3177289A4 (de) 2014-08-08 2018-03-21 Forsight Vision4, Inc. Stabile und lösliche formulierungen von rezeptortyrosinkinaseinhibitoren und verfahren zur herstellung davon
SG11201703726XA (en) 2014-11-10 2017-06-29 Forsight Vision4 Inc Expandable drug delivery devices and method of use
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
CA2982213C (en) 2015-04-09 2022-10-18 Cornell University Gene therapy to prevent reactions to allergens
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
EP3294298A4 (de) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin-analoga, synthese und verwendungen
JP6805174B2 (ja) 2015-05-12 2020-12-23 アメリカ合衆国 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むａａｖ分離株及び融合タンパク質
IL283475B1 (en) 2015-05-28 2024-03-01 Univ Cornell Administering esterase C.1 using adenovirus as a treatment for vascular edema
BR112017025859A2 (pt) 2015-06-03 2018-08-14 Aquesys, Inc. colocação de shunt intraocular ab externo
US20160354161A1 (en) 2015-06-05 2016-12-08 Ortho Kinematics, Inc. Methods for data processing for intra-operative navigation systems
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
EP4086249A3 (de) 2015-09-02 2023-02-15 Trevena, Inc. 6-gliedrige heterozyklen mit delta-opioidrezeptor-modulierenden verbindungen, verfahren zur herstellung und verwendung davon
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US10182939B2 (en) 2015-09-16 2019-01-22 Novartis Ag Hydraulic injector and methods for intra-ocular lens insertion
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
RU2770099C2 (ru) 2015-10-07 2022-04-14 Апеллис Фармасьютикалс, Инк. Схемы введения
JP7408284B2 (ja) 2015-10-30 2024-01-05 エディタス・メディシン、インコーポレイテッド 単純ヘルペスウイルスを治療するためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物
DK3368085T3 (da) 2015-11-01 2024-04-02 Massachusetts Inst Technology Modificerede alginater til anti-fibrotiske materialer og anvendelser
US11180538B2 (en) 2015-11-13 2021-11-23 University Of Utah Research Foundation Combinatorial gene construct and non-viral delivery for anti-obesity
CN108430405B (zh) 2015-11-20 2021-04-13 弗赛特影像4股份有限公司 用于缓释药物递送装置的多孔结构
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
EP3416726A4 (de) 2016-02-17 2019-08-28 Children's Medical Center Corporation Ffa1 (gpr40) als therapeutisches ziel für nervenangiogeneseerkrankungen oder funktionsstörungen
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
WO2017176886A1 (en) 2016-04-05 2017-10-12 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
EP3452165A1 (de) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systeme und verfahren zur verabreichung eines augenmedikaments
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
CA3025526A1 (en) 2016-06-02 2017-12-07 Aquesys, Inc. Intraocular drug delivery
KR20190020318A (ko) 2016-06-13 2019-02-28 메사추세츠 인스티튜트 오브 테크놀로지 이물질 반응 및 섬유화를 감소시키기 위한 생체적합성 코팅 및 하이드로겔
AU2017305404B2 (en) 2016-08-02 2023-11-30 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
WO2018081504A1 (en) 2016-10-28 2018-05-03 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
US11229662B2 (en) 2016-11-15 2022-01-25 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
CN110475548A (zh) * 2016-12-29 2019-11-19 纯比率控股股份有限公司 模块化透皮递送系统以及相关制备和使用方法
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
KR20190129867A (ko) 2017-02-17 2019-11-20 트레베나, 인코포레이티드. 5-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
ES2945740T3 (es) 2017-05-05 2023-07-06 Univ Pittsburgh Commonwealth Sys Higher Education Aplicaciones oculares de vesículas unidas a matriz (MBV)
EP3630042A4 (de) * 2017-05-30 2021-06-23 Eximore Ltd. Zusammensetzungen und verfahren zur behandlung von trockenem auge mittels freisetzung von antibiotischem macrolid
CA3067695A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
KR20200027971A (ko) 2017-07-14 2020-03-13 싸이톰스 테라퓨틱스, 인크. 항-cd166 항체 및 이의 용도
EP4218813A3 (de) 2017-07-27 2023-08-16 Alexion Pharmaceuticals, Inc. Hochkonzentrierte anti-c5-antikörperformulierungen
EP3441069B1 (de) 2017-08-11 2023-04-05 Unity Biotechnology, Inc. Behandlung von diabetischer retinopathie mit pharmazeutischen wirkstoffen zur eliminierung seneszenter zellen
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
BR112020006601A2 (pt) 2017-10-02 2020-12-08 Genedit Inc. Rna guia de cpf1 modificado
WO2019070917A1 (en) 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
AU2018351053A1 (en) 2017-10-18 2020-05-07 Washington University Dominant negative sarm1 molecules as a therapeutic strategy for neurodegenerative diseases or disorders
WO2019090309A1 (en) 2017-11-06 2019-05-09 Massachusetts Institute Of Technology Anti-inflammatory coatings to improve biocompatibility of neurological implants
US11246753B2 (en) 2017-11-08 2022-02-15 Aquesys, Inc. Manually adjustable intraocular flow regulation
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
WO2019133818A1 (en) 2017-12-29 2019-07-04 Cornell University Gene therapy for eosinohilic disorders
WO2019161378A1 (en) 2018-02-19 2019-08-22 University Of Miami Cyclophosphamide for treating ophthalmic inflammation
JP7356994B2 (ja) 2018-03-02 2023-10-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 網膜炎症および神経変性を処置するためのｉｌ－３４の使用
US10952898B2 (en) 2018-03-09 2021-03-23 Aquesys, Inc. Intraocular shunt inserter
US11135089B2 (en) 2018-03-09 2021-10-05 Aquesys, Inc. Intraocular shunt inserter
DE102018106217A1 (de) 2018-03-16 2019-09-19 Amw Gmbh Applikator
CA3095911A1 (en) 2018-04-03 2019-10-10 Cornell University Gene therapy for oxidative stress
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
KR20210052450A (ko) 2018-07-31 2021-05-10 코넬 유니버시티 기관 기능을 제어하기 위한 유전자 요법 방법
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11793834B2 (en) 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
US20220133768A1 (en) 2019-02-25 2022-05-05 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
WO2021022208A1 (en) 2019-08-01 2021-02-04 Kaplitt Michael G Targeted gene therapy to treat neurological diseases
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
US20230313223A1 (en) 2019-10-15 2023-10-05 Cornell University Methods for modulating level of expression from gene therapy expression cassette
US11471426B2 (en) 2019-10-16 2022-10-18 American River Nutrition, Llc Compositions comprising quinone and/or quinol and methods of preparations and use thereof
AU2020367437A1 (en) 2019-10-16 2022-06-02 Cornell University Gene therapy for Alzheimer's disease
US20230001017A1 (en) 2019-10-28 2023-01-05 University Of Lowa Research Foundation Formulation for delivery of lubricin gene
JP2023502515A (ja) 2019-11-25 2023-01-24 コーネル・ユニバーシティー Ａｐｏｅ遺伝子療法
WO2021146625A1 (en) 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of crx-autosomal dominant retinopathies
EP4118202A1 (de) 2020-03-20 2023-01-18 Athanor Biosciences, Inc. Impfstoffe auf bakteriophagenbasis und manipulierter bakteriophagen
WO2021207069A1 (en) 2020-04-05 2021-10-14 Athanor Biosciences, Inc. Bacteriophage-based antibodies and protein-based binders
US20230312639A1 (en) 2020-04-23 2023-10-05 University Of Iowa Research Foundation Gper proteolytic targeting chimeras
BR112022021450A2 (pt) 2020-04-24 2022-12-27 Millennium Pharm Inc O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
WO2022006439A2 (en) 2020-07-02 2022-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compound embodiments for treating retinal degeneration and method embodiments of making and using the same
US20230374483A1 (en) 2020-07-08 2023-11-23 Regents Of The University Of Minnesota Modified hexosaminidase and uses thereof
WO2022036104A1 (en) 2020-08-12 2022-02-17 University Of Iowa Research Foundation Insulin sensitizers for the treatment of diabetes mellitus
US20230293678A1 (en) 2020-08-21 2023-09-21 Aliasger K. Salem Cationic nanoparticle adjuvants
US20230414787A1 (en) 2020-08-27 2023-12-28 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
US20240100183A1 (en) 2020-12-11 2024-03-28 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
WO2022215054A1 (en) 2021-04-09 2022-10-13 Takeda Pharmaceutical Company Limited Antibodies targeting complement factor d and uses therof
EP4323522A1 (de) 2021-04-16 2024-02-21 Editas Medicine, Inc. Crispr/rna-geführte nukleaseassoziierte verfahren und zusammensetzungen zur behandlung von rho-assoziierter autosomal-dominanter retinitis pigmentosa (adrp)
AR125450A1 (es) 2021-04-26 2023-07-19 Millennium Pharm Inc Anticuerpos anti-adgre2 y usos de los mismos
US20230111279A1 (en) 2021-04-26 2023-04-13 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
EP4340894A1 (de) 2021-05-21 2024-03-27 University Of Iowa Research Foundation Antioxidationsmittelhaltige partikel und verfahren zur verwendung
WO2022271951A1 (en) 2021-06-23 2022-12-29 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
TW202306555A (zh) 2021-07-07 2023-02-16 美商建南德克公司 桿插入物系統及方法
AU2022372894A1 (en) 2021-10-20 2024-04-18 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023105417A1 (en) 2021-12-06 2023-06-15 Breye Therapeutics Aps Danegaptide formulation for applicatoin in the eye
WO2023130022A2 (en) 2021-12-29 2023-07-06 University Of Iowa Research Foundation Cystatin rna compositions for tissue engineering
WO2023164727A1 (en) 2022-02-28 2023-08-31 University Of Iowa Research Foundation A-fabp antibodies for diagnosis and treatment of obesity-associated diseases
US20230346862A1 (en) 2022-05-02 2023-11-02 Athanor Biosciences, Inc. Cancer eradicating - bio-nanoparticles (ce-bnp)
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4057619A (en) * 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4210139A (en) * 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4303637A (en) * 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
CA1206049A (en) * 1982-09-30 1986-06-17 Paul E. Michelson Osmotic device for physiological applications
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5330529A (en) * 1993-02-17 1994-07-19 Cepela Mark A Orbital implant device
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants

Also Published As

Publication number Publication date
ES2231781T3 (es) 2005-05-16
CN1139375A (zh) 1997-01-01
EP0729324B1 (de) 2004-09-01
JPH09505300A (ja) 1997-05-27
EP0729324A4 (de) 1997-09-03
AU1092495A (en) 1995-06-06
US5443505A (en) 1995-08-22
WO1995013765A1 (en) 1995-05-26
EP0729324A1 (de) 1996-09-04
ATE274872T1 (de) 2004-09-15
KR960705512A (ko) 1996-11-08
DE69433981T2 (de) 2005-09-01
US5766242A (en) 1998-06-16
US5824072A (en) 1998-10-20
TW368411B (en) 1999-09-01

Similar Documents

Publication Publication Date Title
DE69433981D1 (de) Biocompatibele okulare implantate
CA2030459A1 (en) Biodegradable ocular implants
EP0322319A3 (en) Composition comprising biodegradable ocular implants
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
NO992754L (no) Segmentert bånd for oeyets senehinne for behandling av presbyopi og andre forstyrrelser i oeyner
ES2167611T3 (es) Formulaciones de gel que contienen factores de crecimiento.
WO1995028124A3 (en) An adjunctive polymer system for use with medical device
HUP0001818A2 (hu) A szem első kamrájában alkalmazható szabályzott felszabadulású gyógyszerhatóanyagok
DK0696205T3 (da) Anvendelse af neuro-afledte fetale cellelinier til transplantationsterapi
DE69702273T2 (de) Aktive implantierbare medische Vorrichtung und dazugehörende externe Programmiereinrichtung mit automatischer Aktualisierung von integrierter Software
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DE69814394D1 (de) Verwendung von levobupivacain
ATE110957T1 (de) Pharmazeutische behandlung einer augenentwicklung.
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
ATE343983T1 (de) Ophthalmologisches implantat
WO1995016435A3 (en) Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
BR0215382A (pt) Método e implante intra-esclerótico para o tratamento de glaucoma e presbiopia
CA2176145A1 (en) Biocompatible ocular implants
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
DE69914066T2 (de) Augenspüllösung
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
ES2053834T3 (es) Un metodo para la preparacion de una sustancia terapeutica.
DE69614577D1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
UA28504A (uk) Спосіб лікування співдружньої косоокості

Legal Events

Date Code Title Description
8364 No opposition during term of opposition